TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
2,265,877
|
1,993,782
|
1,688,488 |
| Financial expenses |
113,612
|
104,722
|
44,661 |
| Earnings before taxes |
383,668
|
266,222
|
298,428 |
| EBITDA |
813,912
|
651,947
|
546,984 |
| Total assets |
6,568,058
|
6,671,503
|
4,717,342 |
| Current assets |
1,145,867
|
1,141,943
|
1,007,432 |
| Current liabilities |
1,050,712
|
1,720,890
|
1,335,065 |
| Equity capital |
3,507,248
|
3,052,181
|
2,383,563 |
| - share capital |
16,976
|
17,484
|
15,276 |
| Employees (average) |
1,840
|
1,772
|
1,556 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
53.4%
|
45.7%
|
50.5% |
| Turnover per employee |
1,231
|
1,125
|
1,085 |
| Profit as a percentage of turnover |
16.9%
|
13.4%
|
17.7% |
| Return on assets (ROA) |
7.6%
|
5.6%
|
7.3% |
| Current ratio |
109.1%
|
66.4%
|
75.5% |
| Return on equity (ROE) |
10.9%
|
8.7%
|
12.5% |
| Change turnover |
339,877
|
300,379
|
293,037 |
| Change turnover % |
18%
|
18%
|
21% |
| Chg. No. of employees |
68
|
216
|
-3 |
| Chg. No. of employees % |
4%
|
14%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.